Merck & Company Inc's Fiscal Year is From January To December.
The item "Price-To-Sales-Ratio" stands at 2.67 as of 09/30/2025, the lowest value at least since 06/30/2022, the period currently displayed.
As of the end of Merck & Company Inc's third quarter, the item "Price To Sales Ratio" stands at 2.67. This represents a decrease of -6.91 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -34.08 percent compared to the value the year prior.
The 1 year change in percent is -34.08.
The 3 year change in percent is -15.25.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Sales Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Sales Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price To Sales Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Sales Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Sales Ratio | 280,205,508,085.11 |